Recent cll Articles
Financial and COVID Resources for CLL Patients
Learn about new financial assistance and COVID resources for those living with CLL (chronic lymphocytic leukemia) and those caring for someone who is.
Chemo-Free Treatment Best Option for CLL Patients Under 70
There is good news in the advancement of chemo-free approaches to managing chronic lymphocytic leukemia, and I am thrilled to share it with you. Results of the phase III ECOG trial found that the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) came out superior to the chemotherapy and immunotherapy (chemoimmunotherapy) grouping of fludarabine, cyclophosphamide, and rituximab, known as FCR.
The Original Cancer Immunotherapy: Modifying Our Behavior
We are hearing a lot about cancer immunotherapy these days. Modern approaches and technology are now helping to revolutionize cancer care. What decision-making power do we hold to influence an immune-therapeutic response to help avoid, manage, or treat a cancer diagnosis? And how might this affect long-term survival?
Announcing CLL Society Expert Access™
I recently learned about a new pilot program from my friends at the CLL Society called CLL Society Expert Access™. This important pilot program coordinates free second opinions with CLL experts for CLL patients who have not had or have not been able to secure such access.
[Free Guide] 10 Essential Steps to Take Control of Your Cancer Journey
n of 1 author Glenn Sabin offers 10 important steps to take immediate control of your cancer journey, and to position you at the center of your own care.
Integrative Oncology Circa 1991
In 1991, when I first learned I had an incurable form of leukemia, integrative oncology wasn’t even a term. Integrative cancer care programs were nonexistent at major cancer centers. Put simply, there was nowhere for a newly diagnosed cancer patient like me to turn to learn about patient-centered, integrative approaches to disease management; at least […]
I am an n of 1. You are an n of 1.
Shortly after I was diagnosed with terminal cancer in 1991, my personal n of 1 experiment began; its outcomes have been closely chronicled for a quarter century.
